Century Therapeutics IPSC
NASDAQ IPSC
$1.58 -0.03 (-1.86%)
At close: Oct 22, 2026 · 4:00 PM EDT

Century Therapeutics (IPSC) EBITDA Margin (2022 - 2025)

Updated

Century Therapeutics' EBITDA Margin came in at -3.82% for FY2025, up 1890.75 percentage points from -1894.57% in FY2024.

Analysis

Century Therapeutics (IPSC) EBITDA Margin (2022 - 2025) Analysis & Trends

Going back to FY2022, Century Therapeutics' EBITDA Margin data covers 4 years.

  • EBITDA Margin carries a three-year change of +2408.01 percentage points (FY2022 to FY2025).
  • Per Business Quant, earlier years put EBITDA Margin at -1894.57% in FY2024 (+4078.68 pp), -5973.24% in FY2023 (-3561.41 pp) and -2411.83% in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,230.11 Bn 1,198.70 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 644.39 Bn 564.25 Bn 17.30 Bn 32.68%
3 AbbVie 503.52 Bn 476.68 Bn 12.70 Bn 49.01%
4 Merck 363.29 Bn 317.72 Bn 12.21 Bn 6.02%
5 Novartis Ag 298.23 Bn 262.62 Bn 11.24 Bn -
6 Astrazeneca 267.53 Bn 241.29 Bn 12.86 Bn 33.11%
7 Amgen 241.80 Bn 197.20 Bn 7.24 Bn 46.01%
8 Gilead Sciences 195.07 Bn 169.19 Bn 6.22 Bn -124.26%
9 Pfizer 173.33 Bn 120.28 Bn 10.94 Bn 39.16%
10 Century Therapeutics 285.26 Mn -219.11 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 70.90%
Dec 31, 2024 -813.95%
Sep 30, 2024 -3,981.29%
Jun 30, 2024 -4,058.75%
Mar 31, 2024 -3,284.56%
Dec 31, 2023 -15,003.73%
Sep 30, 2023 -21,808.11%
Jun 30, 2023 -32,126.26%
Mar 31, 2023 -1,692.85%
Dec 31, 2022 -5,834.74%
Sep 30, 2022 -1,298.88%
Jun 30, 2022 -2,120.85%
Mar 31, 2022 -3,421.55%
API Access

Century Therapeutics EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=IPSC&period=max&api_key=YOUR_API_KEY